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Abstract
The effects of homologous plasma HDL and VHDL fractions
on established atherosclerotic lesions were studied in choles-
terol-fed rabbits. Atherosclerosis was induced by feeding the
animals a 0.5% cholesterol-rich diet for 60 d (group 1). An-
other group of animals were maintained on the same diet for 90
d (group 2). A third group was also fed the same diet for 90 d
but received 50 mg HDL-VHDL protein per wk (isolated from
normolipemic rabbit plasma) during the last 30 d (group 3).
Aortic atherosclerotic involvement at the completion of the
study was 34±4% in group 1, 38.8±5% in group 2, and
17.8±4% in group 3 (P < 0.005). Aortic lipid deposition was
also significantly reduced in group 3 compared with group 1
(studied at only 60 d) and group 2. This is the first in vivo,
prospective evidence of the antiatherogenic effect of HDL-
VHDL against preexisting atherosclerosis. Our results
showed that HDL plasma fractions were able to induce re-
gression of established aortic fatty streaks and lipid deposits.
Our results suggest that it may be possible not only to inhibit
progression but even to reduce established atherosclerotic le-
sions by HDL administration. (J. Clin. Invest. 1990.
85:1234-1241.) atherosclerosis * cholesterol-fed rabbit .
HDL-VHDL * regression - lipoprotein
Introduction
The most important characteristic of atherosclerotic arteries is
the accumulation of cholesterol within the vessel wall as a
consequence of an unbalanced cholesterol influx-efflux. "Re-
verse cholesterol transport" seems to be the major route for
removal of the exchangeable cholesterol deposited in tissues
that do not metabolize it, and for its transport to the liver and
subsequent metabolization (1, 2). The concept of a reverse
cholesterol transport pathway, with the HDL particle serving
as scavenger of tissue cholesterol, has been enthusiastically
accepted since it was postulated by Glomset more than 20 yr
ago (3).
The role of plasma HDL as the preferential physiological
acceptor for cholesterol from extrahepatic cells in vivo has
been strongly supported by epidemiologic and in vitro studies
(4-17). Furthermore, we have reported that homologous HDL
plasma fraction (d = 1.063-1.25 g/ml) inhibits the develop-
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ment of fatty streaks and lipid deposition in the aortic wall of
cholesterol-fed rabbits ( 18).
The aim of the present study was to determine whether
homologous HDL-VHDL could affect the progression of es-
tablished atherosclerotic lesions in the cholesterol-fed rabbit.
We found that the plasma lipoproteins of high density were
able to induce regression of the established aortic fatty streaks
and lipid infiltration.
Methods
Animal model. Adult New Zealand white rabbits (3.0±0.5 kg body wt)
were housed in the Animal Research Center of our institution. They
were individually caged in stainless-steel wire-bottomed cages, in a
room controlled to 20±2OC temperature, 50+10% humidity, on a 12-h
light/dark cycle. Our animal care facility is accredited by the American
Association for Accreditation ofAnimal Laboratory Care, and all pro-
cedures were reviewed and approved by the Institutional Animal Care
and Use Committee.
Atherosclerosis was induced by feeding the animals a 0.5% choles-
terol-rich diet at a daily amount of 140 g. The atherogenic diet was
prepared by spraying normal rabbit chow (HF No. 5326; Ralston Pu-
rina Company, St. Louis, MO) with cholesterol dissolved in ethyl-ether
and allowing the solvent to evaporate in a fume hood. Water was
provided ad lib. ( 18, 19).
Preparation and isolation of lipoproteins. Lipoproteins were ob-
tained from normal rabbit plasma according to standard procedures
(20), adjusting densities by KBr as previously described (18, 19). The
lipoprotein fraction selected for our study was obtained at a density
range of 1.063-1.25 g/ml, which includes HDL (d = 1.063-1.21 g/ml)
plus VHDL (d = 1.21-1.25 g/ml). The HDL-VHDL fraction for in-
jection, in all instances < 4 wk old, was sterilized by filtration through
a NALGENE sterilization filter unit type LS with a pore size of0.2 ,m
(Sybron Corp., Rochester, NY).
Protein content of the HDL-VHDL lipoprotein fraction was deter-
mined, after sterilization, by Markwell's modification (21) of Lowry's
method in the presence of SDS using bovine serum albumin as stan-
dard. The purity of the fraction, namely, the absence of apo B, was
tested by SDS polyacrylamide electrophoresis (22) (Fig. 1). The plasma
fraction of HDL contained apo A-I, AII, E, and C's. In addition, this
plasma fraction has been reported to include the lipid transfer proteins,
which enhance transfer and exchange of cholesterol esters, phospho-
lipids, and triglycerides between lipoproteins in plasma (23-27).
The lipid composition per milligram ofprotein ofthe administered
lipoprotein fraction was 0.2±0.03 mg cholesterol, 0.1±0.02 mg triglyc-
erides, and 0.4±0.05 mg phospholipids as determined by specific enzy-
matic assays (Dry Stat; Seragen Inc., Boston, MA, and Wako Pure
Chemical Industries, Ltd., Dallas, TX, respectively). The administered
HDL-VHDL solution had an osmolality of 302 mosmol/liter.
Experimental design. 24 healthy rabbits were selected by body
weight and plasma lipid levels into a homogeneous group. Our "homo-
geneous group" is defined according to the triglycerides and total and
HDL-cholesterol levels obtained from a pool of control rabbits, which
actually comprises more than 250 healthy animals. As described in Fig.
2, all the animals were kept on the same atherogenic diet throughout
the study. The atherogenic diet consisted ofa0.5% cholesterol-rich diet
given at a daily amount of 140 g. After 60 d on the atherogenic diet,
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Figure 1. SDS-polyacrylamide electrophoresis. From left to right: (a)
standard rabbit apolipoproteins A-I and E; (b and c) two different
concentrations of the HDL-VHDL lipoprotein fraction used in our
study; and (d) purified rabbit LDL. The figure shows total absence of
apo B in our HDL-VHDL preparation.
group 1, a randomly selected group of 10 animals, were killed and the
aortic fatty streak formation and cholesterol deposition were studied.
This group provided the baseline for atherosclerotic lesions obtained
before the HDL-VHDL or saline administration. Groups 2 (n = 7) and
3 (n = 7) were studied after 30 more days on the atherogenic diet.
During this period, group 3 received the HDL-VHDL plasma fraction,
while group 2 was kept under the same experimental conditions as
group 3 and served as the atherosclerosis-progression control (placebo
group). Group 3 received 50 mg of HDL-VHDL protein in saline
solution (final volume, 5 ml), given intravenously via the marginal ear
vein once a week during the 4 wk. Group 2 was given saline solution on
the same schedule and under the same conditions as the treated group
(group 3). The animals of these two groups were sacrificed by pairs 1
wk after the last lipoprotein administration.
Morphological and histological evaluation of atherosclerosis. The
rabbits were anesthetized with Ketamine plus Rompun (5 and 35
mg/kg, respectively, given intramuscularly). The carotid artery was
cannulated, and the animals were exsanguinated. After laparotomy
and exposure of the aorta, the animals were killed by an overdose of
anesthetic, and the aortas were perfused in situ with 0.2 M phosphate-
buffered saline containing papaverine (60 mg/500 cm3) at 370C to
avoid vasoconstriction. The aortas were removed intact from the aortic
arch to the iliac bifurcation and were stripped of all adventitial debris.
Thereafter, they were cut lengthwise into two halves through a dorsal
and a ventral incision. Care was taken to dissect between the dorsal
bifurcations so that the flow dividers were evenly split between the two
halves. One half ofeach aorta was fixed in 10% buffered formalin, and
the other half was processed for lipid analysis. The fixed aortas were
stained by Sudan IV to reveal sudanophilic plaques (28). After stain-
ing, the aortas were pinned open to flatten them. A template was then
made for each aorta by tracing the outlines of the aorta and the ather-
omatous lesions on a clear plastic sheet. Each template was magnified
(X2) and photographed. Morphometric assessment of the percentage
of total aorta covered with lipid deposits (Sudan-positive area) was
determined by computerized planimetry (EM image analyzer; model
124; Numonics Corp., Lansdale, PA). Each of three blinded observers
prepared a template for each aorta, and each then performed plani-
metric measurements on his own templates. Inter-observer variation
was < 1%. All measurements were averaged for each aorta.
Since atherosclerotic lesions form at specific sites, such as the bi-
furcation points of branching vessels, we alternated between choosing
the right or left half of each aorta for biochemical or morphological
analysis, so as to compensate for differences between the two halves
and negate possible unequal sectioning.
For light microscopy sections, segments ofthe thoracic aortas after
Sudan IV staining were embedded in paraffin and stained with hema-
toxylin-eosin.
Figure 2. Experimental design of
our study. Group I was killed after
60 d on the atherogenic diet and
served as a control for the extent of
aortic fatty streaks and lipid infiltra-
tion obtained before HDL-VHDL
administration. Groups 2 and 3
were kept on the atherogenic diet
for 30 more days. Group 2 served as
a control of atherosclerosis-progres-
sion and, since it was kept under
the same experimental conditions
(receiving saline solution), served as
a placebo group. Group 3 was given
50 mg HDL-VHDL protein/week
during the last 30 d (atherosclerosis-
progression period).
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Plasma lipid analysis. Blood samples were collected in EDTA (1.5
mg/ml). All the animals were tested for their baseline and killing levels
of total and HDL-cholesterol and triglycerides after 12-16 h fasting.
Plasma was immediately obtained by low speed centrifugation at 4VC.
Aliquots were separated and kept frozen at -70'C until assayed. Cho-
lesterol content was determined using an enzymatic kit (Dry Stat;
Beckman Instruments, Inc., Carlsbad, CA). Triglyceride content of
plasma was measured using an enzymatic kit (Seragen Diagnostics
Inc., Indianapolis, IN) as previously described (18, 19). HDL-choles-
terol was measured in plasma after precipitation of apo B-containing
lipoproteins by PEG-6000 (29), as we have described (18, 19). The
HDL-cholesterol was isolated in an aliquot of fresh plasma and there-
after kept frozen until assayed.
Biochemical analysis of aortic wall and liver. Aortas (half) were
homogenized at 4VC in 5 ml of0.13 M Tris HCO (pH 7.4), 0.01% NaN3
using a homogenizer (Polytron Corp., Elkhart, IN). The total lipids
were extracted from the homogenates in 10 vol of chloroform/metha-
nol (2:1; vol/vol) containing 0.001% butylated hydroxytoluene (2,5-
Di-t-butyl-p-cresol 4-methyl-2,6-test-butylphenol) as an antioxidant. A
second extraction with the Folch procedure was then carried out (30).
The lipid-containing fraction was dried under nitrogen and then
resuspended in isopropyl alcohol (31). The triglycerides, total choles-
terol, and free cholesterol levels were measured by the specific enzy-
matic assays mentioned for plasma lipid analysis; esterified cholesterol
was calculated as the difference between total and free cholesterol.
Phospholipid determinations were performed using an enzymatic kit
(Wako Pure Chemical Industries, Ltd.).
The same procedure was followed with the livers. Livers were ho-
mogenized, and total cholesterol levels measured in the lipid extracts
(31) by using a specific enzymatic assay (Dry Stat; Beckman Instru-
ments, Inc.).
Hematological analysis and animal surveillance. Platelet number,
size, and distribution were determined with a P260 platelet analyzer
(Coulter Electronics Inc., Hialeah, FL) as we have reported (32). Rab-
bit platelets and red blood cells are smaller than those of humans,
therefore, new thresholds had to be defined in the counter to analyze
rabbit blood. After a preliminary study, a lower and upper threshold of
1.73 and 15.7 AMm3, respectively, were determined to include the small-
est platelets and to avoid counting the micro-red blood cells as large
platelets. Hematocrit was also measured by the microhematocrit tech-
nique (Readacrit centrifuge; Clay Adams, Parsippany, NJ).
Animals were closely followed during the experimental period.
Their daily food intake was recorded and their weight taken once a
week to detect any sudden weight loss.
Statistical analysis. Results are expressed as mean±SEM unless
otherwise stated. Multiple group means were compared by single or
multiple factor analysis of variance (ANOVA)' with factorial analysis
and differences between groups analyzed by Fisher protected least
significant difference and Scheffe F tests.
Results
Plasma lipids. All the animals responded to the atherogenic
diet with similar, marked increases in total plasma cholesterol
compared with prediet values (prediet baseline = 61 mg/dl;
60-d level = 1,559 mg/dl) (Fig. 3). At 60 d, group 1 animals
were killed. The remaining animals were randomly divided
into two groups and continued on the atherogenic diet for 30
more days. Plasma cholesterol levels obtained in groups 2 and
3 at 90 d were not significantly different from those obtained at
60 d. There were no differences in total plasma cholesterol,
HDL-cholesterol, or triglycerides between groups 2 and 3 (Fig.
3) after 90 d on the high-cholesterol diet.
1. Abbreviation used in this paper: ANOVA, analysis of variance.
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Figure 3. Plasma levels of total cholesterol, HDL-cholesterol, and tri-
glycerides. Values are expressed as milligram per deciliter; mean±SE.
Baseline corresponds to all the prediet values of all the animals in-
cluded in our study. Group 1 animals were kept for 60 d on the ath-
erogenic diet (atherosclerosis-induction control). Group 2 animals
were kept for 60 d on the atherogenic diet plus 30 more days on the
same diet while receiving saline solution (atherosclerosis progression
control). Group 3 animals were kept 60 d on the atherogenic diet
plus 30 more days on the same diet while receiving HDL-VHDL.
At 90 d, total cholesterol distribution among the different
lipoprotein subfractions was similar in both groups (Table I).
The so-called "atherogenic" lipoproteins (VLDL and LDL; d
< 1.063 g/ml) accounted for more than 95% of the total cho-
lesterol. All groups showed a marked decrease in the choles-
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Table I. Total Cholesterol Distribution
among Plasma Lipoproteins
Group 2 Group 3
VHDL 902±178 811±100
LDL 407±61 398±37
HDL 38±18 37.5±21
Results expressed as milligram per deciliter (mean±SE). Blood sam-
ples were obtained at the end of the experiments, 1 wk after the last
HDL-VHDL administration.
terol carried by the HDL fraction from 43% at baseline to 3%
at killing.
Morphological and histological analysis. Group 1 (athero-
sclerosis control group) were killed 60 d after beginning the
atherogenic diet and served as a reference point for the level of
atherosclerotic lesions achieved in the other 2 groups before
the HDL or saline administration. Groups 2 and 3 were kept
on the same diet for 30 more days and then killed. When the
three groups (groups 1, 2, and 3) were analyzed for the pres-
ence of aortic lipid-rich lesions (fatty streaks), all groups
showed the atherosclerotic lesion distribution and characteris-
tics typical of this experimental model. Lesions consisted of
fatty streaks, affecting mainly the aortic arch and the descend-
ing thoracic aorta. The bifurcation points, such as the inter-
costal ostia, were affected most; the abdominal aorta much
less so.
The aortic atherosclerotic involvement was evaluated by
computerized planimetry of the Sudan IV-positive areas, ex-
pressing the results as a percentage of the total aortic surface
covered by fatty lesion (Fig. 4). Group 1 (60 d on atherogenic
diet) showed 34±4% of the aortic surface affected. After 30
more days on the cholesterol-rich diet, the aortic surface of
group 2 (90 d on atherogenic diet) was 38.8±5% involved. The
results showed a trend toward greater aortic atherosclerotic
involvement, as a consequence of the longer period of athero-
genic diet ingestion, even though it did not reach statistical
significance. In contrast, group 3 (90 d on diet plus HDL-
VHDL) had only 17.8±4. 1% of their aortic surface covered by
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Figure 4. Aortic atherosclerotic involvement. Values are expressed as
%±SE of aortic surface covered by fatty streaks. Analysis of data by
ANOVA (*, P < 0.05 compared with both groups I and 2).
fatty streaks, a statistically significant difference (P < 0.005)
not only compared with group 2 (90 d on diet), but also when
compared even with group 1 (60 d on diet) (P < 0.005).
Histological examination of the aortas of the three groups
of animals revealed similar lesions characterized by accumu-
lation of lipids in the hyperplastic areas ofthe inner layer ofthe
intima (Fig. 5). A decrease in lesion thickness in the group 3
(HDL-VHDL) animals (Fig. 5 A) is evident in comparison
with the animals in groups 1 and 2 (Fig. 5, B and C, respec-
tively).
Lipid accumulation in the aortic wall. To analyze lipid
infiltration, we performed a chemical analysis of the lipids
extracted from the aortic wall. Values of total cholesterol, free
cholesterol, esterified cholesterol, triglycerides, and phospho-
lipids accumulated within the aortic wall are presented in
Fig. 6.
Group 2 (90 d on diet) showed heavier lipid deposition in
the aortic wall than group 1 (atherosclerosis-induction 60 d on
diet), probably due to the longer time on the diet. Group 3
(HDL-treated) had a 55% reduction of total cholesterol (P
< 0.05), 59% reduction of esterified cholesterol (P < 0.05), and
59% reduction of phospholipids (P < 0.05) with no differences
in free cholesterol and triglycerides when compared with group
2. When group 3 was compared with group 1 (only 60 d on
atherogenic diet) significant decreases in total cholesterol (P
< 0.05), free cholesterol (P < 0.05), and phospholipids (P
< 0.05) were also observed (Fig. 6).
Cholesterol accumulation in the liver. The total cholesterol
content in the livers is presented in Fig. 7. HDL-VHDL treat-
ment (group 3) showed a trend toward lesser cholesterol accu-
mulation in the livers even though it did not reach statistical
significance.
Effect of diet and treatment. All groups had similar body
weight gain throughout the experimental period. The HDL-
VHDL-treated rabbits gained an average of 0.85±0.4 kg
(range 0.5-1.0 kg), and group 2 gained an average of 0.7±0.2
kg (ranging from 0.4 to 0.8 kg). No difference in food intake
was observed among groups. Hematocrit, platelet, and red
blood cell counts were similar in all groups. The animals
showed good physical appearance and normal behavior during
the entire experiment.
Discussion
In a previous study we have shown that homologous HDL-
VHDL administered concomitantly with an atherogenic diet
inhibits aortic fatty streak formation and cholesterol deposi-
tion in cholesterol-fed rabbits (18). The present study sought to
determine if homologous HDL-VHDL administration, after
atherosclerotic lesions have been established, could inhibit or
reverse its further development. After the high-cholesterol diet
was given for 60 d, the animals had 34% of their aortic surface
covered by fatty streaks containing 15±2.4 mg ofcholesterol/g
of aorta. These values match those of previous studies using
the same dietary method of atherosclerosis induction (18, 19).
The remaining animals ofthe study were kept on the same diet
for 30 more days with one group (group 3), being given 50
mg/wk of homologous HDL-VHDL protein and the other
(group 2) given saline solution as control.
Our results showed that administration of homologous
HDL-VHDL not only inhibited the progression of established
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Figure 5. Representative aortic sections from
HDL-treated (A), placebo (B), atherosclerotic-con-
trol (C), and normal (D) rabbits. Sections were
taken from similar areas of the thoracic aorta.
Normal animals were fed a standard rabbit chow.
(hematoxylin-eosin stain, X80).
atherosclerotic lesions, when compared with group 2 (90 d on
diet), but also induced significant regression of aortic fatty
streaks and cholesterol deposition when compared with group
1 (atherosclerosis-induction group, 60 d on diet). Therefore,
HDL-VHDL have been shown to reverse the extent of arterial
damage and lipid infiltration induced by 90 d of an athero-
genic diet to levels significantly lower than those achieved after
60 d on the diet. HDL-treated animals (group 3) developed
54% less aortic infiltration with fatty streaks, as determined by
computerized planimetry of the aortic wall, than the control
animals (group 2). Their aortas also contained 56.3% less cho-
lesterol than those of controls.
An abundance of data confirming the inverse relationship
between HDL and arterial atherosclerotic disease have been
reported (4-9). To date, such studies have been retrospective,
and no prospective interventional studies other than ours (18)
have been conducted to test the efficacy ofHDL in preventing
or inhibiting the development of atherosclerotic disease. Stud-
ies in tissue culture systems have lent credence to the hypoth-
esis that HDL protects against the development of atheroscle-
rosis (10-17). Such studies have indicated that HDL may exert
this beneficial effect by facilitating reverse cholesterol trans-
port, namely, transporting cholesterol away from extra-hepatic
tissues and carrying it back to the liver where it can be elimi-
nated (14-16).
Using in vitro systems, other authors have reported that
not only HDL, but also VHDL, may exert an antiatherogenic
effect (14, 16, 33). For example, plasma proteins obtained in
the d> 1.21 g/ml fraction can remove cholesterol from macro-
phages (14, 33), while albumin and 7y-globulins, the two major
proteins of this fraction, did not accept large amounts of cho-
lesterol (14). In our experimental protocol, we used the plasma
fraction obtained at density range 1.063-1.25 g/ml, which
contains HDL2 (d = 1.063-1.12 g/ml) HDL3 (d = 1.12-1.21
g/ml), and VHDL (d = 1.21-1.25 g/ml). In addition, it has
been reported that this density fraction includes the lipid
transfer proteins which have been shown to enhance transfer
and exchange of lipids between lipoproteins in plasma
(23-27). The dosage and frequency ofthe lipoprotein adminis-
tration (50 mg protein content given intravenously once a
week), is the same that successfully inhibited the development
of fatty streak and lipid accumulation in the aortic wall in our
earlier study ( 18).
In the present study, as expected, all the animals rapidly
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Figure 6. Aortic lipid accumulation. Values are expressed as mg/g dry tissue (mean±SE). Data analysis by ANOVA (*, P < 0.05 compared with
groups 1 and 2; +, P < 0.05 compared with group 1; ', P < 0.05 compared with group 2).
developed hypercholesterolemia upon atherogenic diet inges-
tion. No statistically significant difference in plasma lipids was
observed between the groups. Cholesterol distribution among
the different lipoproteins showed that apo-B containing lipo-
proteins (d < 1.063 g/ml) accounted for - 95% of the total
plasma cholesterol, being the ratio of HDL-cholesterol to total
cholesterol markedly reduced in comparison with prediet
levels.
HDL-VHDL treatment induced a significant reduction in
the extent of aortic atherosclerotic involvement when com-
pared with groups 1 and 2. Because plasma lipid levels were
not modified by the treatment, there seems to be a direct role
for HDL in aortic cholesterol metabolism. Similar inhibition
of cholesterol-induced atherosclerosis without change in
plasma lipid levels has been observed in rabbits given estrogens
_i
GROUPS
Figure 7. Hepatic accu-
mulation of total cho-
lesterol. Values are ex-
pressed as mg/g dry tis-
sue (mean±SE).
(34), verapamil (35), a specific thromboxane A2 synthetase
inhibitor (36), polyunsaturated oils (37), and probucol (38,
39). It has also been reported that intravenous administration
of large amounts of dispersed phospholipids (0.5-3.5 g two to
three times a week) induces regression ofexperimental athero-
sclerosis in rabbits (39-41).
In a preliminary study, we reported that HDL stimulated
prostacyclin (PGI2) synthesis by aortic wall in normal (42) and
atherosclerotic rabbits (43). It has been reported that prosta-
glandins modulate arterial cholesteryl-ester metabolism by
stimulating the enzyme cholesteryl-hydrolase (44). Therefore,
an increased prostacyclin production in the HDL-treated
group might also account for the observed antiatherogenic ef-
fect.
It has also been shown that HDL reverses the accumula-
tion of cholesteryl esters by continuous hydrolysis and reester-
ification in macrophage-like cell lines (45).
Of interest is the observation that the HDL-VHDL-treated
group (group 3) presented a lesser extent of aortic fatty streaks
(Sudan IV-positive areas) than did group 1 (atherosclerosis-
induction group) (Fig. 4). A similar finding was observed when
analyzing the lipid accumulation within aortic wall (Fig. 6).
HDL-VHDL treatment not only significantly inhibited aortic
lipid deposition when compared with group 2, but also yielded
a significantly lower lipid accumulation than in group 1. Inas-
much as all the animals had similar levels of plasma choles-
terol available for deposition within vessel wall, our results
strongly support the hypothesis that homologous HDL-VHDL
administration stimulates reverse cholesterol transport from
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extrahepatic tissues to the liver, where it can be metabolized
and excreted. In addition, as shown in Fig. 5, HDL-treated
animals have less subintimal proliferation than groups 1 and 2.
Our results parallel findings obtained in tissue culture ex-
periments (10-17) and support for the first time in vivo, the
hypothesis that HDLs have an antiatherogenic effect. Such
antiatherogenic effect may be mediated through the postulated
role of HDL in reverse cholesterol transport, even though no
conclusive proof could be obtained from our study and more
studies are needed. Regression of atherosclerotic lesions has
been reported by different interventions in animal models (see
references 46-48) and recently in human studies (49), suggest-
ing that a mechanism may exist for removing the cholesterol
accumulated in the vessel wall. The current report is the first
prospective in vivo evidence ofthe inhibitory effect ofHDL in
established atherosclerosis.
In conclusion, our results suggest that it may be possible to
diminish the progression and even reverse already established
atherosclerotic lesions by administration of HDL-VHDL.
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